New drug enters human testing for three debilitating autoimmune conditions

NCT ID NCT06916806

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This early-stage study aims to test the safety and basic effects of a new experimental drug called AZD5492 in adults with lupus, inflammatory muscle diseases, or rheumatoid arthritis. Researchers will give participants one or two doses and closely monitor them for side effects and how the drug behaves in the body over several months. The main goal is to find a safe dose range before testing whether the drug actually helps control these chronic conditions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Anniston, Alabama, 36207, United States
Research Site
WITHDRAWN

Birmingham, Alabama, 35233, United States
Research Site
NOT_YET_RECRUITING

La Jolla, California, 92037, United States
Research Site
NOT_YET_RECRUITING

Sacramento, California, 95817, United States
Research Site
RECRUITING

Iowa City, Iowa, 52242, United States
Research Site
NOT_YET_RECRUITING

Hamilton, Ontario, L8S 4K1, Canada
Research Site
NOT_YET_RECRUITING

Sherbrooke, Quebec, J1G 2E8, Canada
Research Site
RECRUITING

Beijing, 100730, China
Research Site
RECRUITING

Shanghai, 200001, China
Research Site
RECRUITING

Wuhan, 430022, China
Research Site
RECRUITING

Bordeaux, 33000, France
Research Site
RECRUITING

Montpellier, 34295, France
Research Site
RECRUITING

Nancy, 54035, France
Research Site
RECRUITING

Paris, 75013, France
Research Site
RECRUITING

Strasbourg, 67098, France
Research Site
RECRUITING

Toulouse, 31059, France
Research Site
NOT_YET_RECRUITING

Cologne, 50937, Germany
Research Site
NOT_YET_RECRUITING

Erlangen, 91054, Germany
Research Site
NOT_YET_RECRUITING

Magdeburg, 39120, Germany
Research Site
RECRUITING

Bunkyō City, 113-8655, Japan
Research Site
RECRUITING

Kita-gun, 761-0793, Japan
Research Site
RECRUITING

Kitakyushu-shi, 807-8555, Japan
Research Site
RECRUITING

Kyoto, 606-8501, Japan
Research Site
RECRUITING

Nagasaki, 852-8501, Japan
Research Site
RECRUITING

Amsterdam, 1105 AZ, Netherlands
Research Site
WITHDRAWN

Leiden, 2333, Netherlands
Research Site
RECRUITING

Mérida, 06800, Spain
Research Site
RECRUITING

Seville, 41010, Spain
Research Site
RECRUITING

Valladolid, 47012, Spain
Research Site
RECRUITING

Glasgow, G31 2ER, United Kingdom
Research Site
RECRUITING

London, SE5 9RS, United Kingdom
Research Site
RECRUITING

London, WC1E 6JF, United Kingdom
Research Site
RECRUITING

Southampton, SO16 6YD, United Kingdom

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC INFLAMMATORY MYOPATHIES RHEUMATOID ARTHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS